## **DEPARTMENT OF HEALTH SERVICES**

Division of Medicaid Services F-00081 (07/2024)

## STATE OF WISCONSIN

Wis. Admin. Code § DHS 107.10(2)

## FORWARDHEALTH PRIOR AUTHORIZATION / PREFERRED DRUG LIST (PA/PDL) FOR OPIOID DEPENDENCY AGENTS – BUPRENORPHINE

**INSTRUCTIONS:** Type or print clearly. Before completing this form, read the Prior Authorization/Preferred Drug List (PA/PDL) for Opioid Dependency Agents—Buprenorphine Instructions, F-00081A. Prescribers may refer to the Forms page of the ForwardHealth Portal at <a href="https://www.forwardhealth.wi.gov/WIPortal/Subsystem/Publications/">www.forwardhealth.wi.gov/WIPortal/Subsystem/Publications/</a> ForwardHealthCommunications.aspx?panel=Forms for the completion instructions.

Pharmacy providers are required to have a completed PA/PDL for Opioid Dependency Agents–Buprenorphine form signed and dated by the prescriber before calling the Specialized Transmission Approval Technology-Prior Authorization (STAT-PA) system or submitting a PA request on the Portal, by fax, or by mail. Prescribers and pharmacy providers may call Provider Services at 800-947-9627 with questions.

SECTION I – MEMBER INFORMATION			
1. Name – Member (Last, First, Middle Initial)			
2. Member ID Number	3. Date of Birth – Member		
SECTION II - PRESCRIPTION INFORMATION			
4. Drug Name	5. Drug Strength		
6. Date Prescription Written	7. Refills		
8. Directions for Use			
9. Name – Prescriber			
10. Address – Prescriber (Street, City, State, Zip+4 Code)			
11. Phone Number – Prescriber	12. National Provider Identifier (NPI) – Prescriber		
SECTION III - CLINICAL INFORMATION (Required for A	All PA Requests)		
13. Diagnosis Code and Description			
14. Is the member 16 years of age or older?	☐ Yes ☐ No		
15. Is the member taking any other opioids, tramadol, or carisoprodol?			



PA/PDL for Opioid Depend F-00081 (07/2024)	lency Agents – Buprenorphine
40 1. 41	

Page 2 of 3
-------------

16. Is the member pregnant?			☐ Yes ☐ No		
			2 163 2 110		
If yes, indicate the member's expect	ted delivery date (mr	n/dd/ccyy).			
1					
SECTION IV – ADDITIONAL CLINICAL INFORMATION FOR NON-PREFERRED BUPRENORPHINE-NALOXONE DRUG REQUESTS (PA requests for non-preferred buprenorphine-naloxone drugs may not be submitted via STAT-PA.)					
17. Provide detailed clinical justification buprenorphine-naloxone tablets, Suuse buprenorphine-naloxone tablets member receive a non-preferred bu Suboxone film, and Zubsolv.	uboxone film, and Zu s, Suboxone film, and	bsolv. Include clinical d Zubsolv and why it i	information why the member cannot s medically necessary that the		
SECTION V - AUTHORIZED SIGNATI	URE				
18. SIGNATURE – Prescriber		19. Date Signed			
SECTION VI – FOR PHARMACY PRO	VIDERS USING STA	AT-PA			
20. National Drug Code (11 Digits)		21. Days' Supply Requested (Up to 183 Days)			
22. NPI		,			
23. Date of Service (DOS) (mm/dd/ccyy) (For STAT-PA requests, the DOS may be up to 31 days in the future or up to 14 days in the past.)					
24. Place of Service					
25. Assigned PA Number					
26. Grant Date	27. Expiration Date		28. Number of Days Approved		

SECTION VII – ADDITIONAL INFORMATION
29. Include any additional information in the space below. Additional diagnostic and clinical information explaining the need for the drug requested may be included here.